Women’s telehealth company Wisp, has launched its diagnostics vertical, adding at-home testing capabilities to its platform serving more than 1.5 million customers in the United States.
The new Wisp At-Home Testing & Follow-Up Care service allows patients to collect samples at home for various health conditions without visiting a clinic, addressing provider shortages and improving access to testing. The company’s care team provides follow-up care based on results, keeping patients within the Wisp ecosystem rather than referring them to external partners.
“Integrating diagnostics into Wisp’s already comprehensive care offerings was a natural evolution for the company,” said Monica Cepak, Wisp CEO. “We’re simplifying the path to complete, 360-degree care — making it possible for patients to access testing and treatment from the comfort of home.”
The diagnostics vertical launches with three STI testing panels: the Common STI Panel testing for chlamydia, gonorrhea, and trichomoniasis; a 3-Site Panel for chlamydia and gonorrhea; and an M-Gen Panel for mycoplasma genitalium. These conditions are among the most common STIs, particularly for women under 25.
Patients in all 50 states can order test kits, provide swab and urine samples, and ship them to CLIA/CAP accredited labs using prepaid labels. Results are delivered within 3-5 business days, with follow-up care provided as needed.
According to Wisp’s latest survey, 62% of patients expressed interest in STI testing, with STI, STD, and herpes categories growing 40% year-over-year. The company emphasizes that its testing kits are priced at the lowest market rate and include free consultations.
“At Wisp, we’re committed to breaking down barriers in women’s healthcare,” said Dr. Jillian LoPiano, MD, MPH, FACOG. “By partnering with labs that meet the highest clinical standards for accuracy, and offering streamlined access to treatment when it’s needed, we’re not just improving convenience—we’re helping to destigmatize sexual health.”
The diagnostics launch follows Wisp’s expansion into fertility and weight care verticals, as well as growth in its menopause category. The company plans to introduce hormonal health testing kits later this year and add in-home blood draw services for fertility and menopause care.
